The Roden Lab has a strong tradition of translating research
from the bedside to the bench and back again.
The overarching theme of our research is how genomic variation affects variability in disease susceptibility and response to drug treatment.
Our focus at the bench is on abnormalities of cardiac rhythm, and individual projects incorporate the expertise of the laboratory in mining electronic health records (EHRs) and in basic electrophysiologic methods, including the use of emerging medium and high-throughput approaches for functional genomics.
Principal Investigator Dr. Dan Roden is a leading researcher in pharmacogenomics and personalized medicine. In addition to the active projects listed below, he directed Vanderbilt’s site in the NIH’s Pharmacogenetics Research Network (PGRN) and the American Heart Association’s Strategically Focused Atrial Fibrillation Research Network (AF-SFRN).
Dr. Roden has been Principal Investigator for Vanderbilt’s large BioVU resource that links DNA samples from more than 300,000 patients to their deidentified EHRs since the program was launched in 2007.
The eMERGE network’s long-term goal is to understand how best to implement genomic discovery to enable “Genomic Medicine,” the idea that genomic information will be used to guide individual treatments.
Dr. Roden has served as Vanderbilt site PI for eMERGE since the network started in 2007.
All of Us
The All of Us initiative aims to recruit at least 1,000,000 Americans, including those not usually represented in biomedical research.
Dr. Roden serves as co-PI of the All of Us Data and Research Center.